<DOC>
	<DOC>NCT02702323</DOC>
	<brief_summary>This study mainly evaluate the clinical effect of Apatinib in the treatment of patients with pulmonary metastasis of hepatocellular carcinoma.Half of participants will receive Apatinib and transcatheter arterial chemoembolization (TACE) therapy in combination,while the other half will receive TACE therapy alone.</brief_summary>
	<brief_title>Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study</brief_title>
	<detailed_description>Apatinib is a VEGFR targeting tyrosine kinase inhibitor, which has preliminary demonstrated the efficacy and safety in treatment of advanced hepatocellular carcinoma by phase II stage research. Pulmonary metastasis of hepatocellular cancer is one of the difficulties in clinical practice,because it's not sensitive to systemic chemotherapy.This phase Ⅲ study aims to evaluates the efficacy and safety of the Apatinib in the treatment of advanced hepatocellular cancer with pulmonary metastasis.</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms, Second Primary</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>clinical diagnosis of hepatocellular carcinoma refused to sorafenib treatment have at least one measurable pulmonary lesions expected survival time ≥ 12 weeks within four weeks before the study received radiotherapy or chemotherapy With a variety of factors influencing oral drugs taking and absorption (such as unable to swallow, chronic diarrhea and intestinal obstruction)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>pulmonary metastasis</keyword>
	<keyword>Apatinib</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>